News

In his new role Mr Gudbranson will be responsible for all aspects of Invacare’s finance, treasury, internal audit, investor relations, and information technology functions. Mr Gudbranson replaces Gregory

AVP-21D9 is a human monoclonal antibody product candidate that is being developed as an intravenous treatment for patients with symptoms of anthrax disease following exposure to Bacillus anthracis.

The assets acquired include products such as the DSB (Detachable Silicone Balloon) and the NDSB (Non-Detachable Silicone Balloon), also known as the Endeavor Balloon Catheter, both of which

The SBIR grant, valued at $600,000 over 2 years, will support work being conducted at GenVec, the Vaccine and Infectious Disease Institute at Fred Hutchinson Cancer Research Center

The complexity of pricing systems and varied reimbursement rates for drugs, coupled with different purchasing powers and healthcare systems across Europe pose a formidable obstacle for the adoption

The office intends to investigate the practice of using biomarkers such as blood sugar in diabetics and cholesterol levels among those at risk of heart disease, in evaluating

This second round, led by TxCell’s longstanding investors Auriga Partners, AXA Private Equity, Bioam Gestion, CDC Innovation and Seventure, will allow the company to progress its development programs

The patents protect the use of this substance as a pharmaceutical product in these countries. The two patents granted now expand the scope of protection for BF-1, which

In the past five years, the company has experienced a 150% increase in employees at its US headquarters. The new building will have the capacity for more than